دورية أكاديمية
Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) – study protocol for a randomised controlled trial
| العنوان: | Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) – study protocol for a randomised controlled trial |
|---|---|
| المؤلفون: | Kelly, Peter, Weimar, Christian, Lemmens, Robin, Murphy, Sean, Purroy, Francisco, Arsovska, Anita, Bornstein, Natan M, Czlonkowska, Anna, Fischer, Urs, Fonseca, Ana Catarina, Forbes, John, Hill, Michael D, Jatužis, Dalius, Korv, Janika, Kruuse, Christina, Mikulik, Robert, Nederkoorn, Paul J, O’Donnell, Martin, Sandercock, Peter, Tanne, David, Tsivgoulis, Georgios, Walsh, Cathal, Williams, David, Zedde, Marialuisa, Price, Christopher I |
| المصدر: | European stroke journal, London : SAGE Publications Ltd, 2021, vol. 6, iss. 2, p. 222-228 ; ISSN 2396-9873 ; eISSN 2396-9881 |
| سنة النشر: | 2021 |
| المجموعة: | LSRC VL (Lithuanian Social Research Centre Virtual Library) / LSTC VB (Lietuvos socialinių tyrimų centras virtualią biblioteką) |
| مصطلحات موضوعية: | Ischaemic stroke, inflammation, colchicine, randomised controlled trial |
| الوصف: | Background Inflammation contributes to unstable atherosclerotic plaque and stroke. In randomised trials in patients with coronary disease, canukinumab (an interleukin-1B antagonist) and colchicine (a tubulin inhibitor with pleiotropic anti-inflammatory effects) reduced recurrent vascular events. Hypothesis: Anti-inflammatory therapy with low-dose colchicine plus usual care will reduce recurrent vascular events in patients with non-severe, non-cardioembolic stroke and TIA compared with usual care alone. Design CONVINCE is a multi-centre international (in 17 countries) Prospective, Randomised Open-label, Blinded-Endpoint assessment (PROBE) controlled Phase 3 clinical trial in 3154 participants. The intervention is colchicine 0.5 mg/day and usual care versus usual care alone (antiplatelet, lipid-lowering, antihypertensive treatment, lifestyle advice). Included patients are at least 40 years, with non-severe ischaemic stroke (modified Rankin score ≤3) or high-risk TIA (ABCD2 > 3, or positive DWI, or cranio-cervical artery stenosis) within 72 hours-28 days of randomisation, with qualifying stroke/TIA most likely caused by large artery stenosis, lacunar disease, or cryptogenic embolism. Exclusions are stroke/TIA caused by cardio-embolism or other defined cause (e.g. dissection), contra-indication to colchicine (including potential drug interactions), or incapacity for participation in a clinical trial. The anticipated median follow-up will be 36 months. The primary analysis will be by intention-to-treat. Outcome The primary outcome is time to first recurrent ischaemic stroke, myocardial infarction, cardiac arrest, or hospitalisation with unstable angina (non-fatal or fatal). Summary CONVINCE will provide high-quality randomised data on the efficacy and safety of anti-inflammatory therapy with colchicine for secondary prevention after stroke. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | http://vu.lvb.lt/VU:ELABAPDB98696057&prefLang=en_USTest |
| الإتاحة: | https://doi.org/10.1177/2396987320972566Test http://vu.lvb.lt/VU:ELABAPDB98696057&prefLang=en_USTest |
| رقم الانضمام: | edsbas.4B9890B8 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |